Community Practice Connections™: 16th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Release Date: April 10, 2020
Expiration Date: April 10, 2021

Activity Overview

Millions of people are diagnosed with skin cancer each year, and for many years, available treatments were limited and patient outcomes were less than ideal. In the past several years, a greater understanding of the biology of these diseases has led to a number of new and emerging agents that have revolutionized the treatment for these malignancies.

This Community Practice Connection™ program includes excerpts from the 16th Annual International Symposium on Melanoma and Other Cutaneous Malignancies^®, held in February 2020. This online activity focuses on the practical aspects of clinical care for patients with melanoma and nonmelanoma skin cancer, with some future-looking education, and is designed for those who did not attend the live symposium and to help reinforce learnings for those who did.

Acknowledgement of Support

This activity is supported by educational grants from Array BioPharma, Inc., Bristol Myers Squibb, Genentech, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with melanoma and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Recognize best practices from the latest clinical trials in cutaneous malignancies to manage the full range of cutaneous malignancies across stages of disease
• Assess best practices for multidisciplinary identification and management of the adverse events associated with treatment across cutaneous malignancies
• Outline best practices for use of biomarkers in personalizing care in patients with melanoma, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies
• Contextualize current evidence in terms of evolving standards of care to support the optimal sequencing of therapies across melanoma, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Rodabe N. Amaria, MD
Associate Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Bristol Myers Squibb, Iovance Biotherapeutics, Merck, Novartis.

Omid Hamid, MD
Chief, Translational Research and Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director, Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, CA

Disclosures: Grant Research Support: Arcus Biosciences, Aduro Biotech, Akeso, Amgen, Array BioPharma, Bristol Myers Squibb, CytomX, Exelixis, Roche Genentech, GlaxoSmithKline, Immunocore, Incyte, Iovance Biotherapeutics, Merck, Moderna, Merck Serono, NextCure, Novartis, Sanofi/Regeneron, Seattle Genetics, Torque, Zelluna Immunotherapy; Consultant: Aduro Biotech, Akeso, Amgen, Array BioPharma, BeiGene, Bristol Myers Squibb, Roche Genentech, GlaxoSmithKline, Immunocore, Incyte, Janssen, Merck, NextCure, Novartis, Sanofi/Regeneron, Seattle Genetics, Tempus, Zelluna Immunotherapy; Speakers Bureau: Array BioPharma, Bristol Myers Squibb, Novartis, Sanofi/Regeneron.

Ragini Kudchadkar, MD
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

Disclosures: Grant Research Support: Merck, Regeneron Pharmaceuticals; Consultant: Array BioPharma, Bristol Myers Squibb, Genentech, Immunocore, Regeneron Pharmaceuticals.

Bruce L. Levine, PhD
Barbara and Edward Netter Professor in Cancer Gene Therapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: Lilly Asia Ventures, Novartis, Terumo Corporation; Shareholder: Tmunity Therapeutics; Other: Scientific Advisory Boards: Avectas, Brammer Bio/Thermo Fisher Viral Vector Services, Immuneel Therapeutics, Incysus, Ori Biotech, Vycellix.

Jason J. Luke, MD, FACP
Associate Professor of Medicine
University of Pittsburgh School of Medicine
Director, Cancer Immunotherapeutics Center
UPMC Hillman Cancer Center
Pittsburgh, PA

Disclosures: Grant Research Support: (All to institution for clinical trials unless noted) AbbVie, Agios (IIT), Array BioPharma (IIT), Astellas Pharma, Boston Biomedical, Bristol Myers Squibb, CheckMate (SRA), Compugen, Corvus Pharmaceuticals, EMD Serono, Evelo Biosciences (SRA), Five Prime Therapeutics, FLX Bio, Genentech, lmmatics, lmmunocore, lncyte, Leap Therapeutics, Medlmmune, MacroGenics, Nektar Therapeutics, Novartis, Palleon Pharmaceuticals (SRA), Merck, Spring Bank Pharmaceuticals, Tesaro, Tizona Therapeutics, Xencor; Consultant: AbbVie, Akrevia Therapeutics, Aligos Therapeutics, Array BioPharma, Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, EMD Serono, IDEAYA Biosciences, lncyte, Janssen, Merck, Mersana Therapeutics, Novartis, RefleXion, Silicon Therapeutics, Tesaro, Vividion Therapeutics; Other: Data and Safety Monitoring Board: TTC Oncology; Scientific Advisory Board: 7 Hills Pharma, Actym Therapeutics, Alphamab Oncology, Mavupharma (now part of AbbVie), Pyxis Oncology, Spring Bank, Tempest Therapeutics; Travel: Akrevia Therapeutics, Bayer, Bristol Myers Squibb, EMD Serono, lncyte, Janssen, Merck, Mersana Therapeutics, Novartis, Pyxis Oncology, RefleXion; Patents: (both provisional) Serial #15/612,657 (Cancer lmmunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).

Michael A. Postow, MD
Medical Oncologist
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Array BioPharma, Bristol Myers Squibb, Infinity Pharmaceuticals, Merck, Novartis, RGenix; Consultant: Aduro Biotech, Array BioPharma, Bristol Myers Squibb, Incyte, Merck, NewLink Genetics, Novartis; Other: Honoraria from Bristol Myers Squibb and Merck.

Amod A. Sarnaik, MD
Associate Professor of Oncology and Surgery University of South Florida
Surgical Oncologist
Department of Cutaneous Oncology Immunology Program
Melanoma Center of Excellence Moffitt Cancer Center
Tampa, FL

Disclosures: Grant Research Support: Iovance Inc., Provectus Inc.; Consultant: Iovance Inc.; Other: Sponsored Travel from Iovance Inc.

Ryan J. Sullivan, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Translational Research, Center for Melanoma
Medical Oncologist
Massachusetts General Hospital
Principal Investigator
Dana-Farber/Harvard Cancer Center
Boston, MA

Disclosures: Grant Research Support: Amgen, Merck; Consultant: Amgen, Compugen, Genentech, Merck, Novartis, Replimune, Syndax Pharmaceuticals.

Jeffrey S. Weber, MD, PhD
Professor of Oncology
Department of Medicine
Deputy Director, Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures: Grant Research Support: NextCure; Consultant: Amgen, Bristol Myers Squibb, Celldex Therapeutics, CytomX, EMD Serono, GlaxoSmithKline, Merck, Novartis, Pfizer; Shareholder: Altor, Biond Biologics, CytomX; Other: Patent holder for a PD-1 marker named by Biodesix, and for a CTLA-4 biomarker named by Moffitt Cancer Center.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.